On April 2, 2025 Flamingo Therapeutics ("Flamingo") reported its participation in the following upcoming investor conferences (Press release, Flamingo Therapeutics, APR 2, 2025, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-participation-in-upcoming-investor-conferences-2 [SID1234651757]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Needham 24th Annual Virtual Healthcare Conference, April 7-10, 2025
Wells Fargo Virtual Private Biopharma Symposium, May 7, 2025
During these events, Company management will participate in one-on-one meetings with investors. At the Needham event, Stéphane van Rooijen, President and CEO of Flamingo, and Andrew E. Denker, MD, PhD, Chief Medical Officer, will present a virtual company overview on April 10, 2025, at 11:45 am ET.